Results 41 to 50 of about 1,009 (151)

A Rare Case of Blastic Plasmacytoid Dendritic Cell Neoplasm in a Child Mimicking Lymphoma/Leukemia Cutis

Dermatopathology, 2022
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare tumor that affects elderly individuals and presents a poor prognosis. Skin is the most common site of involvement, accounting for 89% of the cases.
Phanitchanat Phusuphitchayanan, Voraphol Vejjabhinanta, Chayamon Takpradit, Poonnawis Sudtikoonaseth, Manasmon Chairatchaneeboon, Thamonpan Kiatvichukul, Sanya Sukpanichnant   +6 more
doaj   +1 more source

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in an Elderly Female: A Rare Rash

Journal of Community Hospital Internal Medicine Perspectives, 2023
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a rare hematologic malignancy derived from type 2 Dendritic cells (immature Plasmacytoid dendritic cells). It is an aggressive lymphoma and most commonly presents as nonpruritic cutaneous lesions. It can also involve the bone marrow, lymph nodes, or circulating peripheral blasts. Here we present a
Al-Alwan, Ahmad, Khalid, Farhan, Vyas, Charmee, Sirpal, Vishakha, Bader, Husam   +4 more
openaire   +2 more sources

Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN)

Bone Marrow Transplantation, 2021
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is an aggressive hematological malignancy; however, some patients achieve durable remission with allogeneic hematopoietic cell transplantation (allo-HCT). We report on all 17 patients with BPDCN who underwent allo-HCT at our center between 2000 and 2020. The median age was 39 (18-67) years.
Qaiser Bashir, Denái R. Milton, Uday R. Popat, Partow Kebriaei, Chitra Hosing, Issa F. Khouri, Katayoun Rezvani, Yago Nieto, Betul Oran, Samer A. Srour, Neeraj Y. Saini, Amanda L. Olson, Sairah Ahmed, Gheath Al-Atrash, Gabriela Rondon, Marina Y. Konopleva, Richard E. Champlin, Elizabeth J. Shpall, Muzaffar H. Qazilbash, Naveen Pemmaraju   +19 more
openaire   +2 more sources

Unusual presentation of blastic plasmacytoid dendritic cell neoplasm: Pitfalls in other hematolymphoid neoplasms

Human Pathology: Case Reports, 2020
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare CD4+/CD56+ hematological malignancy with aggressive clinical course and poor prognosis.
Alexis Trecourt, Brigitte Balme, Marie-Hélène Lorton, Juliette Fontaine, Pauline Desormeaux, Cédric Rossi, Jean-Noël Bastie, Ingrid Lafon, Géraldine Jeudy, Sophie Dalac, Sarah Huet, Pierre Sujobert, Claire Mauduit, Alexandra Traverse-Glehen   +13 more
doaj   +1 more source

How to Treat Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patients : Results on 86 Patients of the French BPDCN Network

Blood, 2015
Abstract Blastic plasmacytoid dendritic cell neoplasm is a rare and aggressive neoplasm for which there is still no current consensus on the best therapeutic approach. Most patients respond to intensive chemotherapy, but relapses are almost inevitable with median overall survival (OS) in the largest patient series ranging from 8 to 12 ...
Eve Poret, Chrystelle Vidal, Yohan Desbrosses, Fanny Angelot Delettre, Maider Pagadoy, Aurore Pugin, Louis Benazet, Franck Leroux, Elise Robert, Delphine Binda, Sabeha Biichle, Anne Roggy, Laure Philippe, Berengere Gruson, Anne-Claire Gac, Michel Maigre, Denis Caillot, Remy Gressin, Pascal Turlure, Anne-Sophie Michallet, Lila Gilis, Veronique Dorvaux, Yazid Arkam, Caroline Bonmati, Pierre Péterlin, Pierre-Simon Rohrlich, Thorsten Braun, jean-Valere Malfuson, Didier Bouscary, Eric Pujade-Lauraine, Felipe Suarez, Carole Soussain, Etienne Lengliné, Mathieu Puyade, Tony Marchand, Denis Guyotat, Bruno Lioure, Christian Recher, Damien Roos-Weil, Fabrice Jardin, Jean-Pierre Marolleau, Bernard Drenou, Bernard Bonnotte, Sophie Dalac, Philippe Saas, Francine Garnache Ottou, Eric Deconinck   +46 more
openaire   +1 more source

Overcoming Tagraxofusp-Erzs Monotherapy Resistance in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in a Real-World Clinical Setting [PDF]

Journal of Immunotherapy and Precision Oncology
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and clinically aggressive hematologic malignancy with limited treatment options.
Prajwal Dhakal, Mario Sy, Grerk Sutamtewagul, Eric Mou, Nanmeng Yu, Naveen Pemmaraju   +5 more
doaj   +1 more source

Structural design and property regulation of organic polymers for photocatalytic synthesis of H2O2

InfoScience, EarlyView.
Photocatalytic synthesis of H2O2 offers a sustainable approach. Photocatalytic efficiency depends critically on interfacial electron transfer kinetics and spatial charge separation. Herein, we systematically analyze key factors governing photogenerated carrier dynamics and propose engineered strategies to optimize performance, thereby providing design ...
Mingyang Xu, Rongchen Shen, Yingyin Mo, Guijie Liang, Shijie Li, Peng Zhang, Xiaobo Chen, Youji Li, Xin Li   +8 more
wiley   +1 more source

Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm

Therapeutic Advances in Hematology, 2019
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a clinically aggressive hematologic malignancy derived from precursors of dendritic cells and involves most frequently the skin, bone marrow and lymph nodes. Diagnosis depends upon identification of
Minas P. Economides, Marina Konopleva, Naveen Pemmaraju   +2 more
doaj   +1 more source

Frequent NPM1 mutation, monoblastic/monocytic origin and prognostic significance of organ and system involvement in myeloid sarcoma: a multicenter study

The Journal of Pathology: Clinical Research, Volume 12, Issue 2, March 2026.
Abstract Myeloid sarcoma (MS) is a tumorous extramedullary proliferation of blast or blast equivalent cells (e.g., promonocytes or promyelocytes). The most frequent cutaneous presentation is often referred to as leukemia cutis (LC). These lesions, especially without the clinical context of a known bone marrow disease, pose a differential diagnostic ...
Alex Jenei, Béla Kajtár, Tamás László, Hazem A Juratli, Livia Vida, Ágota Szepesi, Réka Mózes, Botond Timár, Jörg Halter, Stefan Dirnhofer, Alexandar Tzankov   +10 more
wiley   +1 more source

High ORRs Seen with Tagraxofusp-erzs in BPDCN [PDF]

Cancer Discovery, 2019
Abstract Tagraxofusp-erzs is an effective therapy for blastic plasmacytoid dendritic-cell neoplasm, according to recently published results from a multistage trial that led to the drug's 2018 approval. In the trial, the drug elicited high overall response rates, and many patients went on to receive a stem-cell transplant.
openaire   +1 more source